- Home
- MIRM vs SNX Comparison
MIRM vs SNX Comparison
Compare MIRM & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | SNX |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 19.4B |
| IPO Year | 2019 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MIRM | SNX |
|---|---|---|
| Price | $93.90 | $262.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $119.85 | ★ $198.70 |
| AVG Volume (30 Days) | 423.1K | ★ 484.0K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | ★ 74.59 | 25.16 |
| EPS | N/A | ★ 8.19 |
| Revenue | $19,138,000.00 | ★ $20,053,764,000.00 |
| Revenue This Year | $26.22 | $9.11 |
| Revenue Next Year | $22.04 | $5.69 |
| P/E Ratio | ★ N/A | $32.87 |
| Revenue Growth | N/A | ★ 17.65 |
| 52 Week Low | $63.23 | $142.22 |
| 52 Week High | $130.00 | $296.47 |
Technical Indicators
Market Signals| Indicator | MIRM | SNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 52.68 |
| Support Level | $95.68 | $248.86 |
| Resistance Level | $98.03 | $263.94 |
| Average True Range (ATR) | 3.70 | 6.96 |
| MACD | 0.37 | 0.84 |
| Stochastic Oscillator | 21.15 | 59.50 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.